Zsofia Sztupinszki, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
BRCA2 Protein | 4 | 2022 | 702 | 0.860 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1042 | 0.680 |
Why?
|
Mutation | 6 | 2021 | 29253 | 0.380 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2021 | 2076 | 0.270 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4748 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8560 | 0.260 |
Why?
|
Prostatic Neoplasms | 3 | 2023 | 10595 | 0.250 |
Why?
|
Receptors, Formyl Peptide | 2 | 2021 | 153 | 0.240 |
Why?
|
Templates, Genetic | 1 | 2021 | 206 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 205 | 0.210 |
Why?
|
Viral Tail Proteins | 1 | 2020 | 7 | 0.210 |
Why?
|
Neoplasms | 5 | 2021 | 20515 | 0.200 |
Why?
|
Poly I-C | 1 | 2020 | 112 | 0.200 |
Why?
|
Toll-Like Receptor 3 | 1 | 2020 | 82 | 0.190 |
Why?
|
Replication Protein A | 1 | 2020 | 65 | 0.190 |
Why?
|
Cytological Techniques | 1 | 2021 | 214 | 0.190 |
Why?
|
Sesquiterpenes | 1 | 2020 | 181 | 0.180 |
Why?
|
DNA Repair | 4 | 2023 | 2031 | 0.180 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 1044 | 0.180 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 617 | 0.170 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2022 | 1395 | 0.160 |
Why?
|
Bacteriophages | 1 | 2020 | 350 | 0.160 |
Why?
|
Gene Amplification | 1 | 2021 | 1078 | 0.150 |
Why?
|
Antigen Presentation | 1 | 2022 | 1251 | 0.150 |
Why?
|
DNA Replication | 2 | 2022 | 1419 | 0.150 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2022 | 1841 | 0.130 |
Why?
|
Ligands | 1 | 2020 | 3286 | 0.120 |
Why?
|
Artifacts | 1 | 2021 | 1912 | 0.120 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3050 | 0.110 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1985 | 0.110 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4285 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2983 | 0.100 |
Why?
|
DNA Damage | 1 | 2020 | 2429 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4910 | 0.090 |
Why?
|
Crohn Disease | 1 | 2022 | 2251 | 0.090 |
Why?
|
Genes, BRCA2 | 2 | 2023 | 591 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3670 | 0.090 |
Why?
|
Immunotherapy | 2 | 2022 | 4088 | 0.090 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13619 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 2718 | 0.080 |
Why?
|
Models, Statistical | 1 | 2021 | 5091 | 0.070 |
Why?
|
Melanoma | 1 | 2022 | 5246 | 0.060 |
Why?
|
Humans | 16 | 2023 | 715594 | 0.060 |
Why?
|
Janus Kinase 1 | 1 | 2022 | 100 | 0.060 |
Why?
|
Ribonuclease H | 1 | 2022 | 49 | 0.060 |
Why?
|
DNA Contamination | 1 | 2021 | 16 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2022 | 97 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6588 | 0.050 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2020 | 76 | 0.050 |
Why?
|
Normal Distribution | 1 | 2021 | 283 | 0.050 |
Why?
|
Cell Line, Tumor | 3 | 2021 | 16726 | 0.050 |
Why?
|
H-2 Antigens | 1 | 2020 | 399 | 0.050 |
Why?
|
Rad51 Recombinase | 1 | 2020 | 184 | 0.050 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 386 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17399 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 28991 | 0.040 |
Why?
|
Hydroxyurea | 1 | 2020 | 290 | 0.040 |
Why?
|
Computational Biology | 2 | 2021 | 3564 | 0.040 |
Why?
|
Cross Reactions | 1 | 2020 | 876 | 0.040 |
Why?
|
GTP Phosphohydrolases | 1 | 2021 | 510 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2021 | 1351 | 0.040 |
Why?
|
Organ Specificity | 1 | 2021 | 2034 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2021 | 1772 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 645 | 0.040 |
Why?
|
Ubiquitination | 1 | 2020 | 989 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1246 | 0.030 |
Why?
|
DNA Helicases | 1 | 2020 | 824 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2200 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1644 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2021 | 1800 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1632 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2021 | 1439 | 0.030 |
Why?
|
Feces | 1 | 2020 | 1373 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3248 | 0.030 |
Why?
|
Epitopes | 1 | 2020 | 2646 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3521 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 6476 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1567 | 0.030 |
Why?
|
Cell Cycle | 1 | 2020 | 2985 | 0.030 |
Why?
|
Regression Analysis | 1 | 2021 | 6498 | 0.030 |
Why?
|
Models, Genetic | 1 | 2021 | 3522 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3569 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 6028 | 0.020 |
Why?
|
Mice | 3 | 2021 | 80270 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2822 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8647 | 0.020 |
Why?
|
Male | 3 | 2023 | 350143 | 0.020 |
Why?
|
Proteomics | 1 | 2021 | 3252 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9838 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4466 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2023 | 5190 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4264 | 0.020 |
Why?
|
Female | 2 | 2021 | 377052 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6659 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5338 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5407 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9494 | 0.020 |
Why?
|
Animals | 3 | 2021 | 169173 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2021 | 8028 | 0.020 |
Why?
|
Phenotype | 1 | 2021 | 16302 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19529 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9544 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2022 | 15606 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18175 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13761 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2022 | 62039 | 0.010 |
Why?
|